<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603300</url>
  </required_header>
  <id_info>
    <org_study_id>INT301-101</org_study_id>
    <nct_id>NCT04603300</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut.</brief_title>
  <official_title>A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrommune Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrommune Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, single-center, randomized, double-blind, placebo-controlled study in adult&#xD;
      participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive&#xD;
      either an escalating dose of INT301 or placebo. The treatment group will be blinded to the&#xD;
      investigator, participants, and the Intrommune study team.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind is controlled by IWRS</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of INT301 compared to placebo in adult peanut allergic participants as measured by dose escalation during study.</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Percentage of participants able to consistently tolerate the protocol-specified highest dose; Incidence of systemic and non-systemic adverse reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacologic requirements as interventions for peanut allergic participants experiencing adverse events on INT301.</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Number of participants requiring treatment for systemic reactions related to experimental treatment or placebo; Number of adverse events requiring treatment for systemic reactions related to experimental treatment or placebo; Adherence to study treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To explore changes in peanut-specific IgG4 and IgE levels in participants (exploratory outcome).</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Change from baseline of peanut-specific IgG4 and IgE in study subjects (exploratory outcome)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INT301 dosing as determined by cohort assignment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as determined by cohort assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INT301</intervention_name>
    <description>INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fully functional toothpaste containing no immunotherapy agents</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participant must be 18-55 years of age inclusive, at the time of signing the informed&#xD;
        consent.&#xD;
&#xD;
        Female participants of childbearing potential or male participants with female partners of&#xD;
        child-bearing potential must utilize highly effective birth control method(s) throughout&#xD;
        the study and for 30 days after the final dose of study drug. Acceptable methods of&#xD;
        contraception include: complete abstinence, male or female condoms with spermicide, oral or&#xD;
        implanted contraceptives, or vasectomy.&#xD;
&#xD;
        For female participants of child-bearing potential: Negative serum beta human chorionic&#xD;
        gonadotrophin (HCG) pregnancy test at screening.&#xD;
&#xD;
        Capable of giving signed informed consent as described in Appendix 1 which includes&#xD;
        compliance with the requirements and restrictions listed in the informed consent form (ICF)&#xD;
        and in this protocol.&#xD;
&#xD;
        Meets at least one of the following conditions&#xD;
&#xD;
          -  Positive skin prick test (SPT) (wheal at least 3 mm greater than control) AND/OR&#xD;
             Peanut specific IgE &gt;.35 kU/L&#xD;
&#xD;
          -  Convincing clinical history of allergic reaction to peanut within 1 hour of ingestion&#xD;
             for at least 3 months prior to screening.&#xD;
&#xD;
          -  Failed an oral food challenge (OFC) of &lt; 100mg of peanut protein at screening.&#xD;
&#xD;
          -  Participant willing and able to undergo the procedures required by the protocol,&#xD;
             including, assessment completion, protocol compliance, and participation in the&#xD;
             placebo dosing period(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or&#xD;
             neurologic compromise (cyanosis or oxygen saturations &lt; 92% at any stage, hypotension,&#xD;
             confusion, collapse, loss of consciousness, or incontinence)&#xD;
&#xD;
          -  Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular,&#xD;
             hematologic, or pulmonary disease) which would make the subject unsuitable for&#xD;
             induction of food reactions&#xD;
&#xD;
          -  Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease&#xD;
&#xD;
          -  Psychiatric disorders that the Investigator believes will interfere with study&#xD;
             assessments&#xD;
&#xD;
          -  Uncontrolled asthma, defined by at least one of the following conditions:&#xD;
&#xD;
               -  - FEV1 &lt;80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC)&#xD;
                  &lt;75% of predicted, with or without controller medications.&#xD;
&#xD;
               -  - Inhaled corticosteroids (ICS) dosing of &gt;500mcg daily fluticasone (or&#xD;
                  equivalent ICS based on NHLBI dosing chart.&#xD;
&#xD;
               -  - One hospitalization in the past year for asthma&#xD;
&#xD;
               -  - An ER visit for asthma within six months prior to screening&#xD;
&#xD;
          -  Planned dental surgery during from screening until study exit&#xD;
&#xD;
          -  Moderate or advanced periodontal disease.&#xD;
&#xD;
          -  Current pregnancy or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erick B Berglund, PhD</last_name>
    <phone>646.895.0741</phone>
    <email>eberglund@intrommune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Nelson, JD</last_name>
    <email>mnelson@intrommune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hudson-Essex Allergy</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Flores</last_name>
      <phone>201-320-7677</phone>
      <email>jflores@circuitclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weiss Medical</name>
      <address>
        <city>Riverdale</city>
        <state>New Jersey</state>
        <zip>07457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Flores</last_name>
      <phone>201-320-7677</phone>
      <email>jflores@circuitclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sheenal Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <keyword>Food allergy</keyword>
  <keyword>Desensitization</keyword>
  <keyword>Allergy Immunotherapy</keyword>
  <keyword>OMIT</keyword>
  <keyword>OIT</keyword>
  <keyword>EPIT</keyword>
  <keyword>SLIT</keyword>
  <keyword>Oral Mucosal Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

